Applied DNA Sciences, through its subsidiary Applied DNA Clinical Labs (ADCL), has expanded its clinical testing services for mpox, leading to a 37% surge in its stock price. The new service now includes detection of both Mpox Clade I and Clade II, aiming to bolster efforts to combat the rising mpox threat.
Results for: APDN
Applied DNA Sciences (APDN) saw its stock price surge on Friday after submitting a validation package to the New York State Department of Health (NYSDOH) for its Linea Mpox Virus 1.0 Assay. The company seeks to expand the assay’s use to detect both clade I and clade II of the mpox virus, potentially increasing its testing capabilities and revenue.